Evidence map›Paper›PMID 35715143›Full record

ReviewSurgical oncology clinics of North America2022

Gastrointestinal Stromal Tumor: New Insights for a Multimodal Approach.

Ashwyn K Sharma, Teresa S Kim, Sebastian Bauer, Jason K Sicklick

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Surgical oncology clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ashwyn K SharmaDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Box 0987, La Jolla, CA 92093, USA.
Teresa S KimDepartment of Surgery, University of Washington, 1959 NE Pacific Street, Box 356410, Seattle, WA 98195, USA.
Sebastian BauerDepartment of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen Hufelandstr. 55, Essen 45122, Germany; DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.
Jason K SicklickDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Box 0987, La Jolla, CA 92093, USA. Electronic address: jsicklick@health.ucsd.edu.
University of Washington · US

Funding

Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal TumorR01CA226803 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2019 to 2023
$2.1M
FDA HHS R01 FD006334NCI NIH HHS R01 CA226803
6 · The paper itself

Abstract

Over the past 20 years, gastrointestinal stromal tumor (GIST) has evolved into an increasingly complex clinical entity with ever more challenges. While surgical resection is the gold standard, advancements in genetic testing, therapeutic options, immunotherapy, and management of metastatic disease necessitate a comprehensive, multimodal approach for these tumors. This chapter highlights the importance of genomic testing of GIST, the use of neoadjuvant and adjuvant therapy for localized disease, surgical principles for GIST, as well as current and new approaches for addressing metastatic disease.

Indexed as

Antineoplastic AgentsGastrointestinal Stromal TumorsCombined Modality TherapyHumansNeoadjuvant TherapyAntineoplastic AgentsGastrointestinal Stromal TumorImmunotherapyNext Generation SequencingTyrosine Kinase Inhibitors

Identifiers

PMID35715143
PMCPMC10185044
OpenAlexW4282009622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.